Antineoplastic agents
type: Topic
type: Authority
authoritative label: Antineoplastic agents
marc key: 150 0$aAntineoplastic agents
has narrower authority: Bromebric acid
has narrower authority: Fareston
has narrower authority: Docetaxel
has narrower authority: Antineoplastic antibiotics
has narrower authority: Oxaliplatin
has narrower authority: Neovascularization inhibitors
has narrower authority: Goserelin
has narrower external authority: Antineoplastic agents--Physiological effect
has narrower authority: Vinblastine
has narrower authority: Laetrile
has narrower authority: Krebiozen
has narrower authority: Arabinonucleosides
has close external authority: Antitumorali
has narrower authority: Fluorouracil
has narrower external authority: Antineoplastic agents--Side effects
has narrower authority: Interferon
has narrower external authority: Antineoplastic agents--Mechanism of action
has narrower authority: Tamoxifen
has exact external authority: antineoplastic agents
has narrower authority: Curcumin
has narrower authority: Puromycin
has narrower authority: Phorboxazoles
has narrower external authority: Antineoplastic agents--Synthesis
has narrower authority: Bisantrene hydrochloride
has narrower authority: Quinacrine
has narrower external authority: Antineoplastic agents--Administration
has narrower authority: Octreotide acetate
has narrower authority: Vinorelbine
has broader authority: Drugs
has narrower authority: Azacitidine
has close external authority: Cytostatikum
has close external authority: Anticancéreux
has narrower external authority: Antineoplastic agents--Research
has narrower authority: Lapatinib
has close external authority: Antineoplásicos
has narrower authority: Paclitaxel
has narrower authority: Methotrexate
has narrower authority: Cetuximab
has narrower external authority: Antineoplastic agents--Metabolism
has reciprocal authority: Cancer--Chemotherapy
has narrower external authority: Antineoplastic agents--Analysis
has narrower external authority: Antineoplastic agents--Safety measures
has narrower authority: Vindesine
has narrower authority: Mitoxantrone hydrochloride
has narrower external authority: Antineoplastic agents--Toxicology
has narrower authority: Vincristine
has narrower authority: Bestatin
has narrower authority: Methisazone
has narrower authority: Camptothecin
has narrower authority: Etoposide
has narrower authority: Imatinib
has close external authority: antineoplastic agents
has narrower authority: Antimetabolites
has narrower authority: Lonidamine
has narrower authority: Trastuzumab
has narrower authority: Rituximab
has narrower authority: Folinic acid
has narrower external authority: Antineoplastic agents--Structure-activity relationships
has narrower authority: Fludarabine
has close external authority: Antineoplastic agents
has narrower external authority: Antineoplastic agents--Therapeutic use
has narrower authority: Bevacizumab
has close external authority: 制癌剤
has narrower external authority: Antineoplastic agents--Design
has narrower authority: Cisplatin
is member of MADS collection: collection LCSHAuthorizedHeadings
is member of MADS collection: collection LCSH General
is member of MADS collection: collection SubdivideGeographically
subject of: http://id.loc.gov/resources/works/2125773
subject of: http://id.loc.gov/resources/works/19869815
subject of: http://id.loc.gov/resources/works/13802278
subject of: http://id.loc.gov/resources/works/16750247
subject of: http://id.loc.gov/resources/works/12405255
subject of: http://id.loc.gov/resources/works/15587839
subject of: http://id.loc.gov/resources/works/15313207
subject of: http://id.loc.gov/resources/works/17612305

Bromebric acid
type: Authority
authoritative label: Bromebric acid
type: Concept

Fareston
type: Authority
authoritative label: Fareston
type: Concept

Docetaxel
type: Authority
authoritative label: Docetaxel
type: Concept

Antineoplastic antibiotics
type: Authority
authoritative label: Antineoplastic antibiotics
type: Concept

Oxaliplatin
type: Authority
authoritative label: Oxaliplatin
type: Concept

Neovascularization inhibitors
type: Authority
authoritative label: Neovascularization inhibitors
type: Concept

Goserelin
type: Authority
authoritative label: Goserelin
type: Concept

Antineoplastic agents--Physiological effect
type: Authority
authoritative label: Antineoplastic agents--Physiological effect
type: Concept

Vinblastine
type: Authority
authoritative label: Vinblastine
type: Concept

Laetrile
type: Authority
authoritative label: Laetrile
type: Concept

Krebiozen
type: Authority
authoritative label: Krebiozen
type: Concept

Arabinonucleosides
type: Authority
authoritative label: Arabinonucleosides
type: Concept

Antitumorali
type: Authority
authoritative label: Antitumorali @it
type: Concept

Fluorouracil
type: Authority
authoritative label: Fluorouracil
type: Concept

Antineoplastic agents--Side effects
type: Authority
authoritative label: Antineoplastic agents--Side effects
type: Concept

Interferon
type: Authority
authoritative label: Interferon
type: Concept

Antineoplastic agents--Mechanism of action
type: Authority
authoritative label: Antineoplastic agents--Mechanism of action
type: Concept

Tamoxifen
type: Authority
authoritative label: Tamoxifen
type: Concept

antineoplastic agents
type: Authority
authoritative label: antineoplastic agents
type: Concept

Curcumin
type: Authority
authoritative label: Curcumin
type: Concept

Puromycin
type: Authority
authoritative label: Puromycin
type: Concept

Phorboxazoles
type: Authority
authoritative label: Phorboxazoles
type: Concept

Antineoplastic agents--Synthesis
type: Authority
authoritative label: Antineoplastic agents--Synthesis
type: Concept

Bisantrene hydrochloride
type: Authority
authoritative label: Bisantrene hydrochloride
type: Concept

Quinacrine
type: Authority
authoritative label: Quinacrine
type: Concept

Antineoplastic agents--Administration
type: Authority
authoritative label: Antineoplastic agents--Administration
type: Concept

Octreotide acetate
type: Authority
authoritative label: Octreotide acetate
type: Concept

Vinorelbine
type: Authority
authoritative label: Vinorelbine
type: Concept

Drugs
type: Topic
type: Authority
authoritative label: Drugs
element list: TopicElement
  element value: Drugs
type: Concept

Azacitidine
type: Authority
authoritative label: Azacitidine
type: Concept

Cytostatikum
type: Authority
authoritative label: Cytostatikum
type: Concept

Anticancéreux
type: Authority
authoritative label: Anticancéreux @fr
type: Concept

Antineoplastic agents--Research
type: Authority
authoritative label: Antineoplastic agents--Research
type: Concept

Lapatinib
type: Authority
authoritative label: Lapatinib
type: Concept

Antineoplásicos
type: Authority
authoritative label: Antineoplásicos @es
type: Concept

Paclitaxel
type: Authority
authoritative label: Paclitaxel
type: Concept

Methotrexate
type: Authority
authoritative label: Methotrexate
type: Concept

Cetuximab
type: Authority
authoritative label: Cetuximab
type: Concept

Antineoplastic agents--Metabolism
type: Authority
authoritative label: Antineoplastic agents--Metabolism
type: Concept

Cancer--Chemotherapy
type: ComplexSubject
type: Authority
authoritative label: Cancer--Chemotherapy
component list: Topic
  type: Authority
  authoritative label: Cancer
  element list: TopicElement
    element value: Cancer
component list: Topic
  type: Authority
  authoritative label: Chemotherapy
  element list: TopicElement
    element value: Chemotherapy
type: Concept

Antineoplastic agents--Analysis
type: Authority
authoritative label: Antineoplastic agents--Analysis
type: Concept

Antineoplastic agents--Safety measures
type: Authority
authoritative label: Antineoplastic agents--Safety measures
type: Concept

Vindesine
type: Authority
authoritative label: Vindesine
type: Concept

Mitoxantrone hydrochloride
type: Authority
authoritative label: Mitoxantrone hydrochloride
type: Concept

Antineoplastic agents--Toxicology
type: Authority
authoritative label: Antineoplastic agents--Toxicology
type: Concept

Vincristine
type: Authority
authoritative label: Vincristine
type: Concept

Bestatin
type: Authority
authoritative label: Bestatin
type: Concept

Methisazone
type: Authority
authoritative label: Methisazone
type: Concept

Camptothecin
type: Authority
authoritative label: Camptothecin
type: Concept

Etoposide
type: Authority
authoritative label: Etoposide
type: Concept

Imatinib
type: Authority
authoritative label: Imatinib
type: Concept

Antimetabolites
type: Authority
authoritative label: Antimetabolites
type: Concept

Lonidamine
type: Authority
authoritative label: Lonidamine
type: Concept

Trastuzumab
type: Authority
authoritative label: Trastuzumab
type: Concept

Rituximab
type: Authority
authoritative label: Rituximab
type: Concept

Folinic acid
type: Authority
authoritative label: Folinic acid
type: Concept

Antineoplastic agents--Structure-activity relationships
type: Authority
authoritative label: Antineoplastic agents--Structure-activity relationships
type: Concept

Fludarabine
type: Authority
authoritative label: Fludarabine
type: Concept

Antineoplastic agents
type: Authority
authoritative label: Antineoplastic agents
type: Concept

Antineoplastic agents--Therapeutic use
type: Authority
authoritative label: Antineoplastic agents--Therapeutic use
type: Concept

Bevacizumab
type: Authority
authoritative label: Bevacizumab
type: Concept

制癌剤
type: Authority
authoritative label: 制癌剤
type: Concept

Antineoplastic agents--Design
type: Authority
authoritative label: Antineoplastic agents--Design
type: Concept

Cisplatin
type: Authority
authoritative label: Cisplatin
type: Concept

http://id.loc.gov/resources/works/2125773
type: Work
aap: A clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics

http://id.loc.gov/resources/works/19869815
type: Work
aap: Advances in studies on enzyme inhibitors as drugs

http://id.loc.gov/resources/works/13802278
type: Work
aap: Anticancer agents from natural products

http://id.loc.gov/resources/works/16750247
type: Work
aap: Anticancer agents from natural products

http://id.loc.gov/resources/works/12405255
type: Work
aap: Anticancer drug development

http://id.loc.gov/resources/works/15587839
type: Work
aap: Anticancer drugs

http://id.loc.gov/resources/works/15313207
type: Work
aap: Anticancer therapeutics

http://id.loc.gov/resources/works/17612305
type: Work
aap: Antitumor potential and other emerging medicinal properties of natural compounds

http://id.loc.gov/resources/works/17874955
type: Work
aap: Bloom, Roger Cancer medicine from nature

http://id.loc.gov/resources/works/16492775
type: Work
aap: Bortezomib in the treatment of multiple myeloma

http://id.loc.gov/resources/works/1830605
type: Work
aap: Bucay, José Waizel Cultivo, aislamiento y variación de principios activos de tres especies de plantas, con propiedades anticancerígenas

http://id.loc.gov/resources/works/14581917
type: Work
aap: Cancer

http://id.loc.gov/resources/works/1492046
type: Work
aap: Cancer chemotherapy

http://id.loc.gov/resources/works/1859997
type: Work
aap: Cancer chemotherapy 1

http://id.loc.gov/resources/works/12495390
type: Work
aap: Cancer chemotherapy and biotherapy

http://id.loc.gov/resources/works/14069600
type: Work
aap: Cancer chemotherapy and biotherapy

http://id.loc.gov/resources/works/16275753
type: Work
aap: Cancer chemotherapy and biotherapy

http://id.loc.gov/resources/works/17761218
type: Work
aap: Cancer targeted drug delivery

http://id.loc.gov/resources/works/19805667
type: Work
aap: Cardiotoxicity of chemotherapeutic agents

http://id.loc.gov/resources/works/1005101
type: Work
aap: Carter, Stephen K., 1937- Chemotherapy of cancer

http://id.loc.gov/resources/works/14513366
type: Work
aap: Cell apoptosis research trends

http://id.loc.gov/resources/works/1442897
type: Work
aap: Cell cycle effects of drugs

http://id.loc.gov/resources/works/15070519
type: Work
aap: Checkpoint Responses in Cancer Therapy

http://id.loc.gov/resources/works/1879528
type: Work
aap: Chemotherapy of gynecologic cancer

http://id.loc.gov/resources/works/16768778
type: Work
aap: Chen, Qingqi, 1963- Kang ai xin yao yan jiu zhi nan

http://id.loc.gov/resources/works/1273662
type: Work
aap: Clarysse, A., 1936- Cancer chemotherapy

http://id.loc.gov/resources/works/10455508
type: Work
aap: Colvin, Michael Engineering cancer drugs

http://id.loc.gov/resources/works/11925680
type: Work
aap: Concepts in oncology therapeutics

http://id.loc.gov/resources/works/1476789
type: Work
aap: Concepts, clinical developments, and therapeutic advances in cancer chemotherapy

http://id.loc.gov/resources/works/14751558
type: Work
aap: Delivery of protein and peptide drugs in cancer

http://id.loc.gov/resources/works/14203940
type: Work
aap: Deoxynucleoside analogs in cancer therapy

http://id.loc.gov/resources/works/1407252
type: Work
aap: Developments in cancer chemotherapy

http://id.loc.gov/resources/works/12331456
type: Work
aap: Dose intensity

http://id.loc.gov/resources/works/18009439
type: Work
aap: Doxorubicin

http://id.loc.gov/resources/works/14347345
type: Work
aap: Drugs affecting growth of tumours

http://id.loc.gov/resources/works/16684374
type: Work
aap: Evidence-based anticancer materia medica

http://id.loc.gov/resources/works/1460758
type: Work
aap: Fundamentals of cancer chemotherapy

http://id.loc.gov/resources/works/15307246
type: Work
aap: Getoff, Nikola, 1922- Free radicals effect on cytostatica, vitamins, hormones and phytocompounds with respect to cancer

http://id.loc.gov/resources/works/14861113
type: Work
aap: Harrison's manual of oncology

http://id.loc.gov/resources/works/14274691
type: Work
aap: Heterocyclic antitumor antibiotics

http://id.loc.gov/resources/works/14643728
type: Work
aap: Hoffman, Edward J. Cancer and the search for selective biochemical inhibitors

http://id.loc.gov/resources/works/1164669
type: Work
aap: Immunomodulatory and cytotoxic agents in dermatology

http://id.loc.gov/resources/works/16810466
type: Work
aap: Jin, Tao Wei sheng wu fa jiao sheng chan zi shan chun yan jiu

http://id.loc.gov/resources/works/15699925
type: Work
aap: Kinase inhibitor drugs

http://id.loc.gov/resources/works/2169604
type: Work
aap: Knock, Frances E. Anticancer agents

http://id.loc.gov/resources/works/12045676
type: Work
aap: Kupchan, S. Morris Plants against cancer

http://id.loc.gov/resources/works/15681732
type: Work
aap: Lacroix, Marc, 1963- Molecular therapy of breast cancer

http://id.loc.gov/resources/works/12491044
type: Work
aap: LaValle, James B. The Cox-2 connection

http://id.loc.gov/resources/works/18556825
type: Work
aap: Lednicer, Daniel, 1929- Antineoplastic drugs

http://id.loc.gov/resources/works/18568241
type: Work
aap: Lednicer, Daniel, 1929- Antineoplastic drugs

http://id.loc.gov/resources/works/15882228
type: Work
aap: Macromolecular anticancer therapeutics

http://id.loc.gov/resources/works/15746185
type: Work
aap: Matthews, David J. (David John), 1965- Targeting protein kinases for cancer therapy

http://id.loc.gov/resources/works/14769228
type: Work
aap: Metal compounds in cancer chemotherapy 2005

http://id.loc.gov/resources/works/21065255
type: Work
aap: Metal-based anticancer agents

http://id.loc.gov/resources/works/20278378
type: Work
aap: Metallo-drugs

http://id.loc.gov/resources/works/1654735
type: Work
aap: Molecular orbital calculations for biological systems

http://id.loc.gov/resources/works/14209511
type: Work
aap: Multimodal concepts for integration of cytotoxic drugs

http://id.loc.gov/resources/works/14475488
type: Work
aap: Nanotechnology for cancer therapy

http://id.loc.gov/resources/works/1069012
type: Work
aap: New drugs, concepts, and results in cancer chemotherapy

http://id.loc.gov/resources/works/18471660
type: Work
aap: New skin toxicities for new anticancer therapies

http://id.loc.gov/resources/works/21591063
type: Work
aap: New skin toxicities for new anticancer therapies

http://id.loc.gov/resources/works/16149372
type: Work
aap: Nitric oxide (NO) and cancer

http://id.loc.gov/resources/works/16580102
type: Work
aap: Novel apoptotic drugs in targeting tumor cells

http://id.loc.gov/resources/works/10359538
type: Work
aap: O Ipê roxo (pau d'arco)

http://id.loc.gov/resources/works/12104377
type: Work
aap: Outline of oncology therapeutics

http://id.loc.gov/resources/works/12746938
type: Work
aap: Parfenov, E. A. Biometals and ligands for anticancer drug design

http://id.loc.gov/resources/works/16062462
type: Work
aap: Pentacyclic triterpenes as promising agents in cancer

http://id.loc.gov/resources/works/21557597
type: Work
aap: Pentacyclic triterpenes as promising agents in cancer

http://id.loc.gov/resources/works/18820456
type: Work
aap: Pharmaceutical formulation and medicinal chemistry

http://id.loc.gov/resources/works/21591978
type: Work
aap: Pharmaceutical formulation and medicinal chemistry

http://id.loc.gov/resources/works/15705629
type: Work
aap: Pharmaceutical perspectives of cancer therapeutics

http://id.loc.gov/resources/works/1131719
type: Work
aap: Pharmacokinetics and cancer chemotherapy

http://id.loc.gov/resources/works/11877202
type: Work
aap: Phytochemicals as bioactive agents

http://id.loc.gov/resources/works/1162386
type: Work
aap: Preston, Fredrica A. Memory bank for chemotherapy

http://id.loc.gov/resources/works/17313952
type: Work
aap: Principles of anticancer drug development

http://id.loc.gov/resources/works/10403226
type: Work
aap: Protivoopukholevye soedinenii︠a︡ pi︠a︡ti-nitrofuranovogo ri︠a︡da

http://id.loc.gov/resources/works/1479194
type: Work
aap: Resistance to antineoplastic drugs

http://id.loc.gov/resources/works/17366719
type: Work
aap: Rituximab

http://id.loc.gov/resources/works/21574093
type: Work
aap: Rituximab

http://id.loc.gov/resources/works/15697069
type: Work
aap: Rituximab-mediated molecular signaling and interactions with chemotherapeutic drugs

http://id.loc.gov/resources/works/10359458
type: Work
aap: Rizzini, Jorge A verdade sôbre o ipê-roxo

http://id.loc.gov/resources/works/12045679
type: Work
aap: Shein, P Cancer and a new drug

http://id.loc.gov/resources/works/1426163
type: Work
aap: Silver, Richard T., 1929- A synopsis of cancer chemotherapy

http://id.loc.gov/resources/works/15839154
type: Work
aap: Small molecules in oncology

http://id.loc.gov/resources/works/14348363
type: Work
aap: Sŭmatʻŭ nano ipcha rŭl iyonghan chʻŏnyŏnmul yurae yangni hwalsŏng mulchil (hangamje, myŏnyŏk hwalsŏngje) ŭi yangmul chŏndal yudo misairhwa e kwanhan yŏnʼgu

http://id.loc.gov/resources/works/18465269
type: Work
aap: Targeted therapies for solid tumors

http://id.loc.gov/resources/works/1577541
type: Work
aap: The anticancer drugs

http://id.loc.gov/resources/works/1160470
type: Work
aap: The chemotherapy source book

http://id.loc.gov/resources/works/12309364
type: Work
aap: The chemotherapy source book

http://id.loc.gov/resources/works/14960416
type: Work
aap: The chemotherapy source book

http://id.loc.gov/resources/works/1996625
type: Work
aap: The Chemotherapy source book

http://id.loc.gov/resources/works/2078007
type: Work
aap: The market for cancer therapeutics and diagnostics

http://id.loc.gov/resources/works/1562463
type: Work
aap: The Search for new anticancer drugs

http://id.loc.gov/resources/works/17158184
type: Work
aap: Therapeutic kinase inhibitors

http://id.loc.gov/resources/works/14309641
type: Work
aap: Thurston, David E. Chemistry and pharmacology of anticancer drugs

http://id.loc.gov/resources/works/12749890
type: Work
aap: Treatment of acute leukemias

http://id.loc.gov/resources/works/11167796
type: Work
aap: Voprosy radiobiologii i biologicheskogo deĭstvii︠a︡ t︠s︡itostaticheskikh preparatov

http://id.loc.gov/resources/works/1178997
type: Work
aap: Wilkes, Gail M. 1997-1998 oncology nursing drug handbook

http://id.loc.gov/resources/works/13074777
type: Work
aap: Wilkes, Gail M. Patient education guide to oncology drugs

http://id.loc.gov/resources/works/17515728
type: Work
aap: Zhou, J. (Jiaju) Zhong yao kang ai huo xing cheng fen

Source
citation source: Common usage in oncology.
citation status: found

RecordInfo
record change date: 1986-02-11T00:00:00
record status: new
record content source: dlc

RecordInfo
record change date: 1993-05-03T10:53:17
record status: revised
record content source: dlc

Anticancer agents
type: Label

Antineoplastic drugs
type: Label

Antineoplastics
type: Label

Antitumor agents
type: Label

Antitumor drugs
type: Label

Cytotoxic drugs
type: Label

Inhibitors, Neoplasm
type: Label

Neoplasm inhibitors
type: Label

ChangeSet
subject of change: Antineoplastic agents
creator name: dlc
created date: 1986-02-11T00:00:00
change reason: new

ChangeSet
subject of change: Antineoplastic agents
creator name: dlc
created date: 1993-05-03T10:53:17
change reason: revised

first: TopicElement
  element value: Antineoplastic agents
rest: nil

Topic
type: Variant
variant label: Anticancer agents
element list: TopicElement
  element value: Anticancer agents

Topic
type: Variant
variant label: Antineoplastic drugs
element list: TopicElement
  element value: Antineoplastic drugs

Topic
type: Variant
variant label: Antineoplastics
element list: TopicElement
  element value: Antineoplastics

Topic
type: Variant
variant label: Antitumor agents
element list: TopicElement
  element value: Antitumor agents

Topic
type: Variant
variant label: Antitumor drugs
element list: TopicElement
  element value: Antitumor drugs

Topic
type: Variant
variant label: Cytotoxic drugs
element list: TopicElement
  element value: Cytotoxic drugs

Topic
type: Variant
variant label: Inhibitors, Neoplasm
element list: TopicElement
  element value: Inhibitors, Neoplasm

Topic
type: Variant
variant label: Neoplasm inhibitors
element list: TopicElement
  element value: Neoplasm inhibitors

ClassNumber
code: RC271.C5
has exact external authority: RC271.C5

ClassNumber
code: RS431.A64
has exact external authority: RS431.A64